Clinical TrialMay 14, 2026, 07:02 AM
Camp4 Therapeutics' CMP-002 Shows Significant Seizure Improvement in Preclinical Study
AI Summary
Camp4 Therapeutics announced new preclinical data for CMP-002, its lead therapeutic candidate for SYNGAP1-related disorder (SRD). The data, presented at the TIDES conference, showed that CMP-002 administration led to a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model. This builds on previous findings of neurodevelopmental benefits, suggesting a broad therapeutic impact by restoring SYNGAP1 protein levels. The company plans to advance CMP-002 into a Phase 1/2 clinical trial for SRD in the second half of 2026.
Key Highlights
- CMP-002 significantly improved seizure phenotypes in SYNGAP1 haploinsufficient mouse model.
- Preclinical data presented at TIDES Oligonucleotide & Peptide Therapeutics conference.
- CMP-002 improved seizure threshold and severity of chemically-induced tonic-clonic seizures.
- SYNGAP1-related disorder affects over 10,000 individuals in the United States.
- SRD is characterized by intellectual disability in 100% and epilepsy in 85% of patients.
- Camp4 expects to initiate a Phase 1/2 clinical trial for CMP-002 in 2H 2026.
Price Impact
More from CAMP